IDSA GUIDELINES Bundle (free trial)

Drug-Susceptible Tuberculosis

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: http://eguideline.guidelinecentral.com/i/770889

Contents of this Issue

Navigation

Page 23 of 23

Disclaimer is Guideline attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. is Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. Abbreviations AFB, acid-fast bacilli; CCR5, C chemokine receptor type 5; CYP, cytochrome P450; DOT, directly observed therapy; EMB, ethambutol; FDA, US Food and Drug Administration; HIV, human immunodeficiency virus; IGRA, interferon-γ release assay; IM, intramuscular; INH, isoniazid; INSTI, integrase strand transfer inhibitor; IV, intravenous; Mtb, Mycobacterium tuberculosis; NNRTI, nonnucleoside reverse transcriptase inhibitor; PZA, pyrazinamide; RFB, rifabutin; RIF, rifampin; RPT, rifapentine; SAT, self-administered therapy; TDF, tenofovir disoproxil fumarate; TDM, therapeutic drug monitoring ; TNF, tumor necrosis factor; TSH, thyroid-stimulating hormone; TST, tuberculin skin test e guidelines provide evidence-based recommendations that have been developed using GR ADE (Grading of Recommendations Assessment, Development, and Evaluation) methodolog y. GR ADE involves structured literature review, systematic reviews and meta-analyses of combined data, and expert discussion to assess the certainty in the evidence and determine the strength of each recommendation. Source Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raery A, Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Official American oracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147-195. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10. PMID: 27516382 e guidelines were a cooperative effort among the American oracic Society, Centers for Disease Control and Prevention, and Infectious Diseases Society of America 106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 For additional copies, order at GuidelineCentral.com Copyright © 2016 All rights reserved IDSATUB16113

Articles in this issue

Links on this page

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - Drug-Susceptible Tuberculosis